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Significance of this study
What is already known about this subject?
 ► The effect of flash glucose monitoring has been 
evaluated in randomized controlled trials, but it is 
unclear if these findings are applicable to real-world 
settings.
What are the new findings?
 ► This analysis demonstrates improved glycemic 
measures within the first month of use that is sub-
sequently sustained.
How might these results change the focus of 
research or clinical practice?
 ► These results support the findings of clinical trials 
of the benefits of flash glucose monitoring, and elu-
cidate the factors associated with those benefits in 
real-world use.
ABSTRACT
Objective To assess the role of flash glucose monitoring 
in early and late changes in glycemic markers under real-
life conditions.
Research design and methods Deidentified glucose 
results from 6802 flash glucose monitors were analyzed 
after dividing into high, medium and low-risk groups based 
on tertiles of time spent in hypoglycemia (min/day <70 mg/
dL) or hyperglycemia (hours/day >240 mg/dL). Groups 
were further subdivided into tertiles of glucose scanning 
frequency and glycemic measures analyzed in the first 14 
days and over 6 months.
Results Improvement in dysglycemia mainly occurred in 
the first month of device use. Comparing first and last 14 
study days, high-hyperglycemic-risk individuals showed 
reduced time >240 mg/dL (mean±SEM) from 6.07±0.06 to 
5.73±0.09 hours/day (p<0.0001). High-frequency scanners 
showed 0.82 hours/day reduction in hyperglycemia 
(p<0.0001) whereas low-frequency scanners failed to 
demonstrate a benefit. High-hypoglycemic-risk individuals 
showed reduction in time ≤54 mg/dL from 90±1 to 
69±2 min/day (p<0.0001) comparing first and last 14 
study days. This reduction was evident in both low and 
high-frequency scanners but with reduced hyperglycemic 
exposure in the latter group.
Conclusions Under real-world conditions, flash 
monitoring is associated with rapid and sustained 
reduction in dysglycemia with high-frequency 
scanners demonstrating more significant reduction in 
hyperglycemia.
InTROduCTIOn
Self-monitoring of blood glucose (SMBG) 
using capillary glucose testing remains 
one of the most widely used methods for 
repeated glucose measurements in patients 
with diabetes. Previous work has shown that 
increasing number of SMBG tests is associated 
with lower glycated hemoglobin (HbA1c), 
indicating that frequent testing is neces-
sary to improve glycemic control.1 However, 
SMBG only provides sporadic data and can be 
inconvenient to patients. Continuous glucose 
monitoring (CGM) has the advantage of 
offering a more comprehensive glycemic 
assessment and a number of randomized 
controlled studies have shown that it further 
improves glycemic control.2–5 However, there 
are a number of factors that limit widespread 
use of CGM, including cost and the need for 
regular calibration. The recently released 
FreeStyle Libre flash glucose monitoring 
system (Abbott Diabetes Care, Alameda, CA) 
addressed some of the drawbacks of tradi-
tional CGM by eliminating the need for cali-
bration and simplifying device wear while 
making it more affordable.
Flash glucose monitoring has been previ-
ously evaluated in people with type 1 and type 
2 diabetes6–9 in the IMPACT and REPLACE 
clinical trials, respectively. In patients with 
type 1 diabetes and good diabetes control 
(HbA1c<7.5%), a clinically meaningful 
reduction in time spent in hypoglycemia 
was observed with the use of flash glucose 
monitoring without deterioration in overall 
glycemia assessed as HbA1c. This improve-
ment in hypoglycemia primarily occurred 
during the first 14 days of system use, which 
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was then sustained for 6 months. In patients with type 2 
diabetes and inadequate glycemic control (HbA1c 7.5%–
12%), time spent in hypoglycemia was also reduced by 
flash glucose monitoring, an effect that was sustained 
and associated with the additional reduction in HbA1c 
in patients younger than 65 years of age. However, given 
these studies were undertaken under trial conditions 
and included a relatively small number of patients, it is 
unclear whether these findings are applicable to real-
world settings.
A recent analysis involving over 50 000 users of the 
FreeStyle Libre system under real-world conditions10 has 
demonstrated an inverse correlation between glucose 
scanning frequency and time spent in either hypogly-
cemia or hyperglycemia. While these data indicate that 
frequent glucose scanning is associated with improved 
glycemic markers, it remains to be determined whether 
higher risk glycemic groups benefit from this glucose 
monitoring strategy and whether any improvement in 
glycemia is sustained.
In this report, we analyzed the early and medium-term 
effects of flash glucose monitoring on glycemic outcomes 
in individuals with high exposure to hyperglycemia or 
hypoglycemia, thus representing high-risk subjects. This 
longitudinal study, conducted under real-life settings, 
had three main objectives: (1) to determine longitudinal 
trends and patterns of glycemic measures over a period 
of 6 months; (2) to elucidate trends and patterns of 
glycemic measures during early use of the system, over a 
period of 14 days; and (3) to understand the role of user 
engagement with the device in determining glycemic 
outcomes.
ReseaRCH desIgn and meTHOds
sensors and readers
The commercial availability of the system began in 
September 2014 in seven European countries (Germany, 
UK, France, Italy, Spain, Sweden and Netherlands), and 
subsequently expanded to other countries. The report 
software was available for free download, which included 
an end-user agreement stating that anonymized and 
deidentified system data would be collected by a database 
at each internet-connected use of the software.10
For the 6-month analysis portion of this report, a subset 
of sensors and readers was included in the analysis. 
Sensors were included only if they were operational for 
5 days or longer. Readers were included in the analysis 
only if they were used with at least 12 sensors; however, 
sensors used with any reader beyond the first 12 were not 
analyzed.
Blood glucose testing details
Blood glucose testing frequency during each sensor wear 
was calculated by counting the number of tests divided by 
duration of sensor use. To understand how blood glucose 
testing frequency changed over a 6-month period, test 
frequency was averaged in 14-day periods across readers 
who had at least one blood glucose test (n=2655).
sensor scanning details
Scanning frequency for each sensor was calculated by 
counting the number of scans divided by duration of 
sensor use. To understand how scanning frequency 
changed over a 6-month period, it was averaged in 
14-day periods across readers who had at least 12 sensors. 
Furthermore, to understand user engagement, scan 
frequency variation during the first 14 days was separately 
analyzed.
glycemic measures
Glycemic measures were studied to observe longitudinal 
trends and patterns over a period of 6 months. In order 
to understand how individuals at high risk of hyper-
glycemia or hypoglycemia responded when using the 
system, the starting population was divided into tertiles 
based on time spent in significant hyperglycemia (>240 
mg/dL) and time spent in hypoglycemia (<70 mg/dL) 
during the first 14 days of sensor use. This yielded a total 
of six groups representing high, medium and low risks 
for hyperglycemia or hypoglycemia. The two high-risk 
groups for hyperglycemia and hypoglycemia were further 
subdivided into tertiles of lower, medium and higher 
scanning frequencies. Tertiles were chosen as a method 
of risk stratification in the absence of consensus clinical 
guidelines for time spent in hypoglycemia and absence of 
baseline laboratory HbA1c data.
Furthermore, to determine how glycemic patterns 
change when system use was first initiated, a separate 
analysis was conducted for the first 14 days of sensor wear 
in the subgroups. In order to account for the impact 
of rapid changes during the initial days of use, days 1 
through 56 were combined with 14-day averages from day 
63 to 161 and exponential curve fitting was performed.
Two hyperglycemic and two hypoglycemic measures 
were subsequently analyzed: time spent above 240 and 
180 mg/dL and time spent below 70 and at or below 54 
mg/dL.11
statistical analysis
The database was analyzed by structured query language 
routines, and further summarized by KNIME ( www. 
knime. org), MATLAB and R statistical package ( www. 
r- project. org). Glycemic measures for each reader were 
calculated for every 14-day period and averaged across 
readers to obtain trends by day. Statistical comparisons 
between the first and last 14-day periods were performed 
by pairwise t-tests and p<0.05 was considered statistically 
significant. When the population was stratified based on 
glycemic measures, longitudinal measures were corrected 
for regression to mean effects. Since regression to mean 
effects are dependent on the measurement errors in 
each individual,12 measurement errors were determined 
by calculating the SD of residuals from a regression trend 
during the first six sensors for each individual. Simulations 
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Figure 1 Stratification of the data into high-risk groups for hypoglycemia and hyperglycemia. Top panels show the distribution 
of initial time spent in hyperglycemia (left) and hypoglycemia (right). Individuals whose initial glycemic measures were to the 
right of the second tertile were designated to be in the high-risk group. The high-risk groups were further stratified based on 
average scanning frequency over 6 months as shown in the bottom panels.
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were then performed by randomly adding this error to 
data from each reader and repeating stratification and 
glycemic measure calculation. The average result after 
200 simulations was then used as the corrected value.
ResulTs
user base
After applying the exclusion criteria, a total of 6802 
readers and 66 670 sensors remained for subsequent 
data analysis (median gap between sensors=3.1 hours). 
Readers were divided into tertiles based on time spent 
in hyperglycemia and time spent in hypoglycemia with 
each group being further subdivided into tertiles based 
on scanning frequency as shown in figure 1.
To assess how the risk stratification technique aligns 
with data from randomized clinical trials, baseline hypo-
glycemia (determined for the first 14 days of sensor use) 
in the high-risk group was compared with that in the base-
line period of the intervention group of IMPACT6 and 
was found to be similar. We relied on time spent in hyper-
glycemia as a measure of exposure to high glucose levels, 
which corresponded to using estimated HbA1c>7.5% in 
terms of baseline mean estimated HbA1c and baseline 
mean HA240, supporting the validity of this approach in 
targeting subjects with inadequate glycemic control.
Summary statistics for the various subgroups during 
the first 14 days are summarized in
table 1 for hyperglycemia and table 2 for hypoglycemia.
Only high-risk groups were analyzed for effect on 
glycemic outcomes. Only 472 out of 4536 (10.4%) of the 
individuals were at high risk of both hypoglycemia and 
hyperglycemia. Due to the limited size of this subgroup in 
the study population, further investigation is needed with 
a larger data set to understand the association of flash 
glucose monitoring and glycemic metrics in individuals 
at higher risk of both hyperglycemia and hypoglycemia. 
Two-thirds of all individuals were in either the high-risk 
group for hyperglycemia or hypoglycemia.
Frequency and pattern of scanning and blood glucose testing
A gradual reduction in scanning frequency was observed 
from over 18 scans/day during the first sensor use to 
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Table 1 Summary statistics for the first 14 days of sensor wear after stratification based on risk of hyperglycemia and 
scanning frequency. All values shown for glycemic measures and scanning frequency are average values
Risk of hyperglycemia
(time above 240 mg/dL)
Scanning frequency
All Lower Medium Higher
Low
  n 2267 756 756 755
  HA240 0.62 hours/day (2.6%) 0.63 hours/day (2.6%) 0.63 hours/day (2.6%) 0.59 hours/day 
(2.5%)
  HA180 3.54 hours/day (14.8%) 3.72 hours/day (15.5%) 3.56 hours/day (14.8%) 3.34 hours/day 
(13.9%)
  Scans/day 15.55 8.09 13.79 24.78
Medium
  n 2267 756 756 755
  HA240 2.16 hours/day (9.0%) 2.24 hours/day (9.3%) 2.15 hours/day (9.0%) 2.08 hours/day 
(8.7%)
  HA180 7.11 hours/day (29.6%) 7.18 hours/day (29.9%) 7.11 hours/day (29.6%) 7.03 hours/day 
(29.3%)
  Scans/day 13.58 7.53 12.37 20.84
High
  n 2268 756 756 756
  HA240 6.07 hours/day (25.3%) 6.65 hours/day (27.7%) 5.84 hours/day (24.3%) 5.71 hours/day 
(23.8%)
  HA180 12.01 hours/day 
(50.0%)
12.35 hours/day (51.5%) 11.77 hours/day (49.0%) 11.91 hours/day 
(49.6%)
  Scans/day 11.58 6.19 10.49 18.05
HA180, hours above 180 mg/dL; HA240, hours above 240 mg/dL.
Table 2 Summary statistics for the first 14 days of sensor wear after stratification based on risk of hypoglycemia and 
scanning frequency. All values shown for glycemic measures and scanning frequency are average values
Risk of hypoglycemia
(time below 70 mg/dL)
Scanning frequency
All Lower Medium Higher
Low
  n 2267 756 756 755
  MB70 23 min/day (1.6%) 22 min/day (1.5%) 23 min/day (1.6%) 23 min/day (1.6%)
  MB54 5 min/day (0.4%) 5 min/day (0.4%) 5 min/day (0.4%) 5 min/day (0.4%)
  Scans/day 14.09 7.05 12.49 22.73
Medium
  n 2267 756 756 755
  MB70 75 min/day (5.2%) 75 min/day (5.2%) 74 min/day (5.1%) 75 min/day (5.2%)
  MB54 22 min/day (1.5%) 24 min/day (1.7%) 21 min/day (1.5%) 21 min/day (1.5%)
  Scans/day 13.62 7.33 12.32 21.23
High
  n 2268 756 756 756
  MB70 200 min/day (13.9%) 204 min/day (14.2%) 196 min/day (13.6%) 200 min/day 
(13.9%)
  MB54 90 min/day (6.3%) 98 min/day (6.8%) 88 min/day (6.1%) 85 min/day (5.9%)
  Scans/day 12.99 7.04 11.64 20.28
MB54, minutes at or below 54 mg/dL; MB70, minutes below 70 mg/dL.
Emerging Technologies, Pharmacology and Therapeutics
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Figure 2 Scan frequency and blood glucose (BG) test frequency over 6 months (top panel) and first 14 days (bottom panel).
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about 15 scans/day at the 2-month mark (figure 2, top 
panel). This level of scanning was then maintained for 
the remainder of the analysis period demonstrating that 
users remained engaged with the system. Blood glucose 
testing stayed stable at 0.75/day throughout the anal-
ysis period. To understand how scanning frequency and 
blood glucose testing changes during the first 14 days, 
a day-to-day analysis of scanning frequency and blood 
glucose testing was performed. The plots in figure 2 
(bottom panel) illustrate a high scan rate of 27 scans/day 
on day 1 of sensor use followed by a rapid initial decrease. 
Blood glucose testing after initiating use of flash glucose 
monitoring stabilized to less than one test/day at the end 
of the 14-day period.
glycemic markers during 6 months of use
For high-risk individuals, glycemic measures were 
analyzed to investigate changes during the first 6 months 
of sensor wear. The results are summarized in table 3.
High-risk hyperglycemia group
Comparing the first and last 14 days of sensor wear, indi-
viduals in high-risk tertile for hyperglycemia showed 
reduced time above 240 mg/dL (mean±SE) from 
6.07±0.06 to 5.73±0.09 hours/day (p<0.0001; figure 3).
The reduction in time spent in hyperglycemia was asso-
ciated with minimal change in time at or below 54 mg/dL 
(29±1 to 31±1 min/day, p=0.023). Results when the high-
risk group was subdivided based on overall scan rate are 
presented in figure 4. Comparing the first and last 14-day 
periods, individuals in the high-risk group showed reduced 
time above 240 mg/dL (mean±SE) from 5.71±0.10 to 
4.90±0.14 hours/day in higher scanners (p<0.0001) with 
a limited effect in medium-frequency scanners (from 
5.84±0.09 to 5.47±0.13 hours; p=0.02), whereas no effect 
was detected in low-frequency scanners. The reduction 
in time spent in hyperglycemia in high and medium-fre-
quency scanners was associated with a modest increase 
in time spent below 70 mg/dL (55±2 min to 62±3 min, 
p=0.003 and 72±2 min to 77±3 min, p=0.028 for higher 
and medium-frequency scanners, respectively). No signifi-
cant change was observed in time spent at or below 54 mg/
dL in higher frequency scanners while a small change was 
observed in the medium scanning frequency group (from 
28±1 min to 32±2 min, p=0.035).
High-risk hypoglycemia group
Comparing the first and last 14-day periods, individuals in 
high risk for hypoglycemia group showed reduced time 
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Table 3 Glycemic measures over 6 months for the high risk of hyperglycemia and hypoglycemia groups. All values shown for 
glycemic measures are average values (with SE)
High risk of hyperglycemia
(time above 240 mg/dL) First 14 days Last 14 days
Mean change (relative 
change) P value
All
  HA240 (hours/day) 6.07±0.06 5.73±0.09 −0.34 (−5.6%) <0.0001*
  HA180 (hours/day) 12.01±0.07 11.47±0.09 −0.54 (−4.5%) <0.0001*
  MB70 (min/day) 71±1 74±2 +3 (+4.2%) 0.006*
  MB54 (min/day) 29±1 31±1 +2 (+6.9%) 0.023*
Higher scanning frequency 
  HA240 (hours/day) 5.71±0.10 4.90±0.14 −0.81 (−14.2%) <0.0001*
  HA180 (hours/day) 11.91±0.11 10.84±0.17 −1.07 (−9.0%) <0.0001*
  MB70 (min/day) 55±2 62±3 7 (12.7%) 0.003*
  MB54 (min/day) 21±1 22±1 1 (4.8%) 0.284
Medium scanning frequency 
  HA240 (hours/day) 5.84±0.09 5.47±0.13 −0.37 (−6.3%) 0.02*
  HA180 (hours/day) 11.77±0.11 11.23±0.15 −0.54 (−4.6%) 0.001*
  MB70 (min/day) 72±2 77±3 5 (6.9%) 0.028*
  MB54 (min/day) 28±1 32±2 4 (14.3%) 0.035*
Lower scanning frequency 
  HA240 (hours/day) 6.65±0.12 6.81±0.17 0.16 (2.4%) 0.118
  HA180 (hours/day) 12.35±0.13 12.36±0.17 0.01 (0.1%) 0.837
  MB70 (min/day) 86±3 83±3 −3 (−3.5%) 0.923
  MB54 (min/day) 39±2 38±2 −1 (−2.6%) 0.451
*Statistically significant.
High risk of hypoglycemia
(time below 70 mg/dL) First 14 days Last 14 days
Mean difference 
(relative reduction as 
a %) P value
All
  HA240 (hours/day) 2.07±0.04 2.83±0.06 +0.76 (+36.7%) <0.0001*
  HA180 (hours/day) 5.67±0.06 6.94±0.09 +1.27 (+22.5%) <0.0001*
  MB70 (min/day) 200±2 154±3 −46 (−23.0%) <0.0001*
  MB54 (min/day) 90±1 69±2 −21 (−23.3%) <0.0001*
Higher scanning frequency
  HA240 (hours/day) 1.33±0.05 1.67±0.08 +0.34 (25.6%) <0.0001*
  HA180 (hours/day) 4.46±0.10 5.16±0.14 +0.70 (15.7%) <0.0001*
  MB70 (min/day) 200±3 161±5 −39 (−19.5%) <0.0001*
  MB54 (min/day) 85±2 65±3 −20 (−23.5%) <0.0001*
Medium scanning frequency
  HA240 (hours/day) 2.07±0.07 2.83±0.10 +0.76 (36.7%) <0.0001*
  HA180 (hours/day) 5.77±0.11 7.12±0.15 +1.35 (23.4%) <0.0001*
  MB70 (min/day) 196±3 148±4 −48 (−24.5%) <0.0001*
  MB54 (min/day) 88±2 68±3 −20 (−22.7%) <0.0001*
Lower scanning frequency
  HA240 (hours/day) 2.82±0.08 3.94±0.12 +1.12 (39.7%) <0.0001*
  HA180 (hours/day) 6.77±0.11 8.48±0.16 +1.71 (25.3%) <0.0001*
  MB70 (min/day) 204±3 154±4 −50 (−24.5%) <0.0001*
Continued
Emerging Technologies, Pharmacology and Therapeutics
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High risk of hypoglycemia
(time below 70 mg/dL) First 14 days Last 14 days
Mean difference 
(relative reduction as 
a %) P value
  MB54 (min/day) 98±3 74±3 −24 (−24.5%) <0.0001*
HA180, hours above 180 mg/dL; HA240, hours above 240 mg/dL; MB54, minutes at or below 54 mg/dL; MB70, minutes below 70 mg/dL.
Table 3 Continued
Figure 3 Glycemic measures for the high risk of hyperglycemia group. Plot markers display 14-day averages over 6 months. 
Error bars show 2×SE.
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below 70 mg/dL (mean±SE) from 200±2 to 154±3 min/
day (p<0.0001; figure 5) and time at or below 54 mg/
dL (mean±SE) from 90±1 to 69±2 min/day (p<0.0001; 
figure 5). The reduction in hypoglycemia was associ-
ated with increased time spent in hyperglycemia above 
240 mg/dL from 2.07 to 2.83 hours/day (p<0.0001), 
while time above 180 mg/dL increased from 5.67 to 6.94 
hours/day (p<0.0001).
High, medium and low-frequency scanners all showed 
reduced time below 70 mg/dL (figure 6) with no differ-
ence detected comparing high-frequency and low-fre-
quency scanners (reduction from 200±3 to 161±5 min 
and 204±3 to 154±4 min/day, respectively; p<0.0001 for 
both). Similar data were obtained for time spent at or 
below 54 mg/dL (figure 6). However, a crucial difference 
was detected in time spent in hyperglycemia comparing 
high and low-frequency scanners where low-frequency 
scanners showed a relatively large increase in time spent 
above 240 mg/dL (2.82–3.94 hours/day; p<0.0001) while 
high-frequency scanners showed a much more modest 
increase (1.33–1.67 hours/day; p<0.0001).
glycemic markers during the initial 14 days of Freestyle libre 
use
In a clinical study, typically a few days of blinded glucose 
sensor data are measured when glucose readings are 
recorded but not displayed to the subject. These few 
days of data would represent the baseline with which 
to compare subsequent ‘unblinded’ glucose readings.6 
However, in this analysis blinded baseline data were not 
available. To get a better sense of changes in glycemic 
markers with flash glucose monitoring, data were fit to an 
exponential distribution using daily and 14-day average 
glycemic measures in high scanners with high risk of 
hyperglycemia and separately for high scanners with high 
risk of hypoglycemia.
High-risk hyperglycemia group
In this group, high scanners displayed a total reduc-
tion in time above 240 mg/dL from 6.0 to 4.79 hours/
day with 0.71 hour/day reduction (59%) occurring in 
the first 14 days of sensor use. For hours above 180 mg/
dL, total reduction was from 12.3 to 10.7 hours/day with 
0.97 hour/day reduction (61%) occurring in the first 
14 days of sensor use. The total improvement associated 
with flash glucose monitoring for this subgroup occurred 
within 2 months of sensor use and was sustained over the 
6-month study period (figure 7).
High-risk hypoglycemia group
In high scanners the reduction in time spent below 70 
mg/dL was from 223 to 160 min/day with a reduction 
of 40 min (63%) occurring in the first 14 days of sensor 
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Figure 4 Glycemic measures for the various scanning frequency subgroups in the high risk of hyperglycemia group. Plot 
markers display averages of 14 days over 6 months. Red diamonds are used for low scanners, orange squares for medium 
scanners and green circles for high scanners. Error bars show 2×SE.
Figure 5 Glycemic measures for the high risk of hypoglycemia group. Plot markers display 14-day averages over 6 months. 
Error bars show 2×SE.
Emerging Technologies, Pharmacology and Therapeutics
use. Similarly, total reduction of time spent at or below 
54 mg/dL was from 110 to 65 min/day, with a reduction 
of 41 min (91%) occurring in the first 14 days of sensor 
use. The improvement in hypoglycemia in high scan-
ners occurred quickly in less than 1 month and was then 
sustained over the study period (figure 8).
COnClusIOns
The current longitudinal study was designed to observe 
the impact of the FreeStyle Libre system on glycemic 
markers outside trial settings, thus further informing 
clinical practice. This study in patients with significant 
derangements in glucose levels shows a number of novel 
and clinically important observations: (1) flash glucose 
monitoring in real-life settings is associated with reduc-
tion in both hyperglycemia and hypoglycemia in higher 
risk individuals, an effect that is sustained over 6 months 
of device use; (2) glucose scanning frequency shows an 
inverse correlation with time spent in hyperglycemia and 
clinically significant hypoglycemia in higher risk patients; 
(3) reduction in hyperglycemia is associated with 
minimal increase in clinically significant hypoglycemia 
whereas hypoglycemia reduction results in increased 
time spent in hyperglycemia, an effect that is minimized 
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Figure 6 Glycemic measures for the various scanning frequency subgroups in the high risk of hypoglycemia group. Plot 
markers display 14-day averages over 6 months. Red diamonds are used for low scanners, orange squares for medium 
scanners and green circles for high scanners. Error bars show 2×SE.
Figure 7 Hours per day above 240 mg/dL (left) and 180 mg/dL (right) versus days of sensor use in high scanners in the high 
risk for hyperglycemia group. Error bars show 2×SE. The plot markers (•) show 14-day averages over the analysis period. The 
solid black line describes the exponential fit that was performed to estimate glucose patterns during the first 14 days of use.
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in frequent glucose scanners; (4) reduction in time spent 
in hyperglycemia is more pronounced in high-frequency 
scanners and the improvement continues for 2 months 
before stabilizing; and (5) reduction in time spent in clin-
ically significant hypoglycemia is immediate and mainly 
occurs in the first 14 days of sensor use.
In this study, individuals at high initial risk of hyper-
glycemia and hypoglycemia showed a reduction in the 
respective measures and maintained it over the course of 
approximately 6 months. Scanning frequency remained 
high even after several months of device use with limited 
capillary glucose testing, indicating that individuals 
show confidence in and continue to rely on the system. 
However, it is possible that individuals used alternate 
blood glucose testing meters rather than the one provided 
by the FreeStyle Libre system, and thus the frequency of 
blood glucose testing would be under-represented.
Previous work has shown that frequent capillary 
glucose testing or flash glucose monitoring is associated 
with improved glycemic parameters,1 supporting a role 
for frequent glucose checks to optimize glycemia. These 
positive effects of glucose checks appear to be maintained 
in individuals at high risk of dysglycemia. In those with 
high risk of hypoglycemia who are frequent scanners, 
39 min/day reduction was observed in hypoglycemia 
between the first and last 14 days of sensor use. More-
over, when compared with the first day of system use, 
the reduction in time <70 mg/dL exceeded 1 hour/day. 
Similarly, in frequent scanners in the high-risk hypergly-
cemic group, comparing the first and last 14 days, there 
was a reduction of 0.81 hour/day of glucose >240 mg/
dL. Compared with the first day of system use, the reduc-
tion in time was even more pronounced at 1.21 hours/
day. Within this risk group, an enhanced benefit was seen 
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Figure 8 Minutes below 70 mg/dL (left) and at or below 54 mg/dL (right) versus days of sensor use in high scanners in the 
high risk for hypoglycemia group. Error bars show 2×SE. The plot markers (•) show 14-day averages over the analysis period. 
The solid black line describes the exponential fit that was performed to estimate glucose patterns during the first 14 days of 
use.
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in high-frequency scanners. In both hyperglycemia and 
hypoglycemia risk groups, the majority of the improve-
ment occurred in the first 14 days of system use, although 
continued reduction in hyperglycemia was evident up to 
2 months following device use with sustained benefit at 
6 months.
Importantly, the reduction in hyperglycemia occurred 
with limited increase in clinically significant hypoglycemia, 
which can predispose to adverse clinical outcomes.13–18 
The increase in time spent in clinically relevant hypogly-
cemia was statistically significant. Conversely, the reduc-
tion in hypoglycemia resulted in a significant increase in 
time spent in hyperglycemia, although this increase was 
limited in high-frequency scanners. It can be inferred 
from these results that individuals address the glycemic 
issue that is most relevant to them even at the cost of 
worsening other glycemic metrics. It was also observed 
that the reduction in time spent in hyperglycemia was 
particularly pronounced in high-frequency scanners. 
Collectively, these data indicate that high-frequency scan-
ning is effective at reducing hyperglycemic exposure.
Interestingly, the reduction in clinically significant 
hypoglycemia was immediate and occurred within a few 
days of system use, suggesting that this was done by the 
patient without input from the healthcare professional. 
Therefore, the device represents a cost-effective measure 
to reducing hypoglycemia, particularly in high-risk 
groups of patients. Moreover, these data further support 
the use of continuous glucose data to reduce hypogly-
cemia in diabetes.2–4 19 20
In contrast, the reduction in hyperglycemia appeared 
more gradual, suggesting that this is a more compli-
cated process and requires additional input by the 
patient, healthcare professional or both parties. More-
over, the more impressive reduction in hyperglycemia 
in high-frequency scanners indicates that regular 
glucose data are needed in order to effectively tackle 
hyperglycemia,1 which can be particularly difficult 
in individuals relying on sporadic SMBG for their 
diabetes management. We have observed that once the 
improvements in glycemic markers have taken place, 
these were sustained over a period of 6 months, indi-
cating that continued system use is able to maintain the 
changes in glycemic parameters.
Strengths of the work include conducting the anal-
ysis under real-life settings, the large number of readers 
investigated and the comprehensive assessment of 
hyperglycemia and hypoglycemia. However, there are 
a number of drawbacks that should be acknowledged. 
First, given the analysis was conducted on deidentified 
data, we have no details on these patients and therefore 
age, gender, type of diabetes or hypoglycemic therapies 
are unknown. Second, this was an observational study 
in patients using the flash glucose monitor that may 
have selected a particular group of motivated individ-
uals, which in turn may question generalizability of the 
results. Third, demonstrating a sustained effect over 6 
months is encouraging but longer term follow-up will 
help to understand the clinical use of the device in the 
long run. Finally, it is unclear whether these glycemic 
benefits translate into improved clinical outcomes and 
long-term longitudinal outcome studies are warranted 
to address this point.
In conclusion, our data show that flash glucose moni-
toring, under real-life conditions, significantly improves 
glucose control in subjects at high risk of dysglycemia. 
The improvement in clinically significant hypoglycemia 
with system use is immediate whereas hyperglycemia 
takes longer to improve with both improvements being 
sustained over a period of 6 months. High-frequency 
scanners further benefit by minimizing hyperglycemic 
exposure in these high-risk groups of patients.
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